We came across a bullish thesis on Nektar Therapeutics on Clinical Catalysts’s Substack. In this article, we will summarize the bulls’ thesis on NKTR. Nektar Therapeutics’s share was trading at $35.23 as of January 29th.
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. NKTR has strengthened its immunology platform...
